Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 3/20 | 0.42 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | ETV6 | P41212 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP7 | P09237 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ME2 | P23368 | 1/20 | 0.38 |
| ▸ | ME1 | P48163 | 1/20 | 0.38 |
| ▸ | ME3 | Q16798 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6785651 | 1.00 | EGLN1 (0.42) | EGLN1RETMGLLGPR119PANK3 | |
| SCHEMBL6785900 | 0.90 | MMP13 (0.43) | RETGPR119MMP2MMP1MMP3 | |
| SCHEMBL6785894 | 0.90 | MMP13 (0.43) | RETGPR119MMP2MMP1MMP3 | |
| SCHEMBL6787976 | 0.89 | RET (0.40) | RETMGLLGPR119PANK3RAB9A | |
| SCHEMBL6787183 | 0.89 | RET (0.40) | RETMGLLGPR119PANK3RAB9A | |
| SCHEMBL6785879 | 0.81 | MAPT (0.40) | CNR2MMP2MMP1MMP3MMP7 | |
| SCHEMBL6785884 | 0.81 | MAPT (0.40) | CNR2MMP2MMP1MMP3MMP7 | |
| SCHEMBL6785348 | 0.79 | CYP3A4 (0.41) | RETGPR119MMP7MMP13 | |
| SCHEMBL6785352 | 0.79 | CYP3A4 (0.41) | RETGPR119MMP7MMP13 | |
| SCHEMBL6831648 | 0.79 | RORC (0.35) | RETMGLLGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266764-A1 | Hydroxamic acid derivatives | HANNAH DUNCAN ROBERT | 2004-12-30 | — | — | US | disclosed |
| US-6809100-B2 | 2-(4-(4-FURAN-2-YLPHENYL)PIPERAZINE-1-SULFONYLMETHYL)-N-HYDROXY -3-METHYLBUTYRAMIDE, FOR EXAMPLE; TREATMENT OF CANCER, INFLAMMATION, OR AN AUTOIMMUNE, INFECTIOUS OR OCULAR DISEASE | DARWIN DISCOVERY LTD. (GB) | 2004-10-26 | — | — | US | disclosed |
| US-6787536-B2 | A HYDROXAMIC ACID COMPOUND CONTAINING HETEROAROMATIC RING ATTACHED TO SULFONYL GROUP THROUGH NITROGEN ATOM, INHIBITOR OF MATRIX METALLOPRETEINASE, USEFUL FOR TREATING DEGENERATIVE DISEASES AND CERTAIN CANCER | DARWIN DISCOVERY LIMITED (GB) | 2004-09-07 | — | — | US | disclosed |
| US-20030216404-A1 | Hydroxamic acid derivatives | HANNAH DUNCAN ROBERT (GB) | 2003-11-20 | — | — | US | disclosed |
| EP-1282614-B1 | HYDROXAMIC ACID DERIVATIVES | DARWIN DISCOVERY LTD (GB) | 2003-11-12 | — | — | EP | disclosed |
| US-20020037900-A1 | Hydroxamic acid derivatives | DARWIN DISCOVERY LIMITED (GB) | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037900-A1 | Hydroxamic acid derivatives | ADAM17, ADAM10, ADAM33 | EGLN1 614/4885RET 2667/4885MGLL 3191/4885 |
| US-20030216404-A1 | Hydroxamic acid derivatives | ADAM17, ADAM10, ADAM33 | EGLN1 614/4885RET 2667/4885MGLL 3191/4885 |
| US-20040266764-A1 | Hydroxamic acid derivatives | ADAM17, ADAM10, ADAM33 | EGLN1 614/4885RET 2667/4885MGLL 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.